Oryzon Reports Strong Q1 2026 Data, Expands Clinical Pipeline
Event summary
- Oryzon's iadademstat shows 100% ORR and 93% CRc in first-line AML patients, with data to be presented at EHA 2026.
- Positive updated data from iadademstat in relapsed/refractory FLT3-mut AML accepted at EHA, showing 67% CRc.
- Company maintains strong cash position of $25.4 million as of March 2026.
- Ongoing preparations for FDA protocol resubmission of PORTICO-2 Phase III trial with vafidemstat in aggression in BPD.
- Continued advancement of vafidemstat programs in schizophrenia and autism spectrum disorder.
The big picture
Oryzon's Q1 2026 results highlight its strong execution across both oncology/hematology and CNS franchises. The company's expanding clinical pipeline and positive data from iadademstat trials position it favorably in the competitive biotech landscape. The strategic focus on strengthening IP protection and advancing late-stage development programs underscores Oryzon's commitment to delivering high-value assets in the epigenetics space.
What we're watching
- Clinical Trial Progress
- The pace at which iadademstat clinical trials advance across hematological malignancies and solid tumors will determine the compound's commercial potential.
- Regulatory Approvals
- The success of the FDA protocol resubmission for the PORTICO-2 Phase III trial with vafidemstat will be critical for its late-stage development.
- Financial Sustainability
- How Oryzon manages its cash position and R&D expenses will impact its ability to sustain operations and fund future clinical trials.
Related topics